• Explore /
  • Poster
  • / Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.

Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.

Abstract Video & Slides Poster

Authors

Sajeve Samuel Thomas

Sajeve Samuel Thomas

University of Florida Health Cancer Center at Orlando Health, Orlando, FL

Sajeve Samuel Thomas , Gino Kim In , Bernard Doger , Simon Haefliger , Juan Martin-Liberal , Zelanna Goldberg , Alex Cacovean , Rana Fiaz , Guang Chen , Madan H. Jagasia , Friedrich Graf Finckenstein , Maria Fardis , Antonio Jimeno

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03645928

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9537)

DOI

10.1200/JCO.2021.39.15_suppl.9537

Abstract #

9537

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Daniel Olson

First Author: Amod Sarnaik

First Author: Rongsu Qi

First Author: Jason Alan Chesney